The New Alzheimer’s Blood Test: What It Is and Can You Get It in India?

How the Alzheimer’s Blood Test Works

The Alzheimer’s blood test measures levels of a protein called phosphorylated tau 217 (p-tau217). In Alzheimer’s disease, abnormal tau proteins accumulate in the brain, disrupting neural communication and eventually causing cell death. Crucially, this accumulation begins 15-20 years before cognitive symptoms appear — meaning the biological process of Alzheimer’s is measurable in the blood long before a person notices any memory problems.

The test works by detecting tiny amounts of p-tau217 that leak from the brain into the bloodstream. Elevated p-tau217 levels in the blood correlate strongly with amyloid plaques and tau tangles in the brain — the two hallmark pathological features of Alzheimer’s disease.

How Accurate Is It?

Multiple independent validation studies have produced impressive accuracy figures. A 2020 study in JAMA found that a blood-based p-tau217 test achieved over 90% accuracy in distinguishing Alzheimer’s disease from other forms of dementia. A 2023 study in Nature Medicine validated the test across diverse populations and found sensitivity of 92% and specificity of 91% for detecting Alzheimer’s pathology.

Perhaps most significantly, the blood test has been shown to perform comparably to amyloid PET scanning — a highly accurate but expensive brain imaging procedure that costs $3,000-$5,000 and is not available in most Indian cities. The blood test achieves similar diagnostic accuracy at a fraction of the cost and complexity.

Other Biomarkers Being Tested

P-tau217 is the most advanced biomarker, but several others are being studied:

• Amyloid beta 42/40 ratio: Measures the ratio of two forms of amyloid beta protein; a falling ratio indicates amyloid plaque accumulation
• Neurofilament light chain (NfL): A marker of neuronal damage — elevated in Alzheimer’s and other neurodegenerative conditions
• GFAP (glial fibrillary acidic protein): A marker of astroglial activation; elevated years before symptom onset

Some commercial tests combine multiple biomarkers for higher accuracy. Research into multi-marker panels is ongoing.

Who Should Consider Getting Tested?

The Alzheimer’s blood test is most relevant for:

• People over 50 with a first-degree family history of Alzheimer’s disease
• Those with the APOE4 genetic variant (which triples to quadruples lifetime Alzheimer’s risk)
• Anyone experiencing early cognitive symptoms — increased forgetfulness, word-finding difficulty, or spatial disorientation — who wants diagnostic clarity
• People motivated to take aggressive preventive action with maximum lead time

Population-level screening of all adults is not yet recommended, primarily because current treatment options for those who test positive but are asymptomatic are still limited — though this is changing rapidly as new drugs receive approval.

Can You Get This Test in India?

Access to Alzheimer’s blood tests in India is improving but remains uneven. As of 2026, the test is available at select major hospitals and neurology centres in Delhi, Mumbai, Bengaluru, and Chennai, typically as part of a comprehensive dementia workup ordered by a neurologist or geriatrician. Commercial availability through diagnostic lab chains (SRL, Metropolis, Thyrocare) is expected to expand significantly over the next 1-2 years as the assays become standardised.

For those outside major cities, telemedicine consultations with neurologists who can order tests through reference labs in metropolitan cities offer a practical pathway to access. The cost is currently estimated at Rs. 8,000-15,000 for a comprehensive Alzheimer’s biomarker panel.

What Happens If You Test Positive?

A positive result — indicating elevated Alzheimer’s biomarkers — does not mean you will definitely develop the disease, particularly if you are currently asymptomatic. It indicates elevated biological risk and should prompt:

• Comprehensive cognitive assessment and baseline testing for tracking over time
• Aggressive adoption of evidence-based preventive lifestyle measures (exercise, sleep, diet, cognitive engagement, cardiovascular risk factor management)
• Consideration of clinical trial participation for emerging preventive therapies
• Genetic counselling if not already undertaken
• Referral to a memory clinic for ongoing monitoring

Expert Perspective

“The Alzheimer’s blood test is going to change clinical practice fundamentally — we will move from diagnosing Alzheimer’s when significant brain damage has already occurred to identifying it in the biological phase, when the brain is still largely intact and preventive intervention is genuinely meaningful. For my patients with a family history or the APOE4 gene, I now consider this test as important as a cardiac stress test for those with heart disease risk.”

Important Caveats

• A positive blood test requires confirmation with additional clinical assessment and often imaging before a definitive Alzheimer’s diagnosis is made
• False positives can occur, particularly in people with other neurological conditions that elevate tau or amyloid markers
• Psychological preparation before testing is important — consider genetic counselling and mental health support as part of the testing decision

Frequently Asked Questions

Is the Alzheimer’s blood test available in India?

Yes, at select neurology centres in major cities including Delhi, Mumbai, Bengaluru, and Chennai. Availability through diagnostic lab chains is expanding. A neurologist referral is typically required.

How early can the Alzheimer’s blood test detect the disease?

Research shows elevated p-tau217 and amyloid biomarkers can be detected 15-20 years before the first cognitive symptoms appear — during the “preclinical” phase when the brain still has substantial reserve capacity.

What does a positive Alzheimer’s blood test mean?

A positive result indicates elevated Alzheimer’s biomarkers and biological risk, but not a certainty of developing the disease. It should prompt a comprehensive neurological assessment and aggressive implementation of preventive strategies.

Should everyone over 50 get the Alzheimer’s blood test?

Not necessarily. Current guidelines recommend targeted testing for those with family history, known risk genes (APOE4), or early cognitive symptoms. Universal screening is not yet recommended due to limited preventive treatment options, though this is expected to change as new therapies gain approval.

Related: Dementia Is Not Inevitable: What You Can Do | The APOE4 Gene and Dementia Risk | Brain Health and Alzheimer’s Prevention Guide